Eli Lilly Stock Has Become a Trillion-Dollar Giant. Is It Too Late to Buy?

Eli Lilly Stock Has Become a Trillion-Dollar Giant. Is It Too Late to Buy?

Vandita Jadeja

Thu, September 10, 2026 at 7:35 PM GMT+3 5 min read

Quick Read

• Eli Lilly (LLY) earns a BUY rating with a $1,220 price target, backed by 47% revenue growth and four straight EPS beats.

• Novo Nordisk (NVO) trades at a forward P/E of 14 with just 2% revenue growth, making Lilly's premium valuation at 24x look justified.

• Retatrutide's BLA submission planned for Q1 2027 is the bull catalyst that could drive shares to $1,382, while pricing declines are the primary risk.

• Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Eli Lilly didn't make the cut. Enter your email to see the names that beat LLY. The report is free. Enter your email and see if any of your stocks made the cut.

Eli Lilly has joined the trillion-dollar club, and the question every long-only investor is asking is whether the run has more room. My take: yes, but the easy money is behind us.

Eli Lilly (NYSE:LLY) trades at $1,123.98 with a market cap of $1.002 trillion. Our 24/7 Wall St. price target for Lilly is $1,220.42 over the next 12 months, implying 8.58% upside. The recommendation is buy with high confidence at 90%.

24/7 Wall St. Price Target Summary

How Lilly Got to a Trillion, and Where Shares Sit Now

Shares are up 50.72% over the past year but down 8.61% over the past month as investors digest a scorching run. LLY sits below its 52-week high of $1,292.65 and well above the low of $707.59.

The engine remains Mounjaro and Zepbound: Q2 2026 revenue reached $22.974 billion, up 47.67% year over year, with EPS of $8.38 beating consensus by 27.27%. Mounjaro alone posted $9.94 billion (+91% YoY), and management raised full-year revenue guidance to $85 billion to $87 billion.

Free Report, Just Released

Why Didn't LLY Make The Top 10 List?

24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now. Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.

And LLY didn't make the cut!

The report is free, and you can see why we think each stock is a top investment today.

Enter Your Email and See the Ten →

Bull Case for $1,381 and Higher

The bull path takes LLY to $1,381.62, a 22.92% gain. The catalysts are real. Retatrutide, Lilly's triple-agonist, delivered what management called "unprecedented efficacy" across three Phase 3 trials, with a BLA submission planned for Q1 2027.

Foundayo, the first oral GLP-1 with no food or water restrictions, expanded to 36,000 prescribers, and the Medicare GLP-1 Bridge Program opened access for 20 million eligible Americans at $50 per month. International incretin market share of 55% and China revenue growth of 93% in constant currency show the runway is global.

What Could Go Wrong

The bear scenario takes shares to $1,045.34, a 7% decline. Realized prices fell 13% in Q2, and concentration risk is real, with the incretin franchise generating roughly $14.87 billion of the quarter's revenue.

Acquired IPR&D charges of $2.78 billion pressured reported earnings, and insider activity leans net selling. To be fair, bulls would note the IPR&D charges reflect aggressive pipeline building (Orna, Kelonia, Ajax, Centessa) that expands the long-term shot count, and pricing declines have been more than offset by 60% volume growth.

How Lilly Compares to Novo Nordisk and Merck

Novo Nordisk (NYSE:NVO) is the only true GLP-1 peer, and the valuation gap is stark. NVO trades at a forward P/E of 14 with quarterly revenue growth of just 2.1%, versus Lilly's 47.7%. That gap validates Lilly's premium multiple.

Merck (NYSE:MRK) offers a diversified big-pharma contrast. Merck's forward P/E of 16 looks cheap on paper, but quarterly earnings shrank 19.3% year over year on Keytruda patent-cliff concerns.

The peer set makes our 24/7 Wall St. price target look reasonable: Lilly deserves a premium, but not an unlimited one.

Eli Lilly Price Prediction 2026-2030

The 24/7 Wall St. price target of $1,220.42 and buy rating at 90% confidence reflect a company still executing at the top of its industry.

The tipping factor is guidance: four straight EPS beats and a raised outlook are hard to fade. I'd be a buyer here if retatrutide's BLA stays on track for Q1 2027. I'd stay on the sidelines if realized-price declines accelerate past 13% in coming quarters.

Looking further ahead, here is where our model projects LLY could trade, assuming continued execution.

These projections assume Lilly continues executing on its GLP-1 leadership and pipeline. Significant upside could come from a clean retatrutide launch, while downside risk centers on payer pricing pressure and eventual GLP-1 competition.

Got $1,000? Before You Buy LLY, Read This

If you have cash sitting in your account right now, give this two minutes. After more than two decades of helping investors beat the market, our top analysts at 24/7 Wall St. put together a definitive report on the Top 10 Stocks To Buy Today. And LLY wasn't one of them.

They combed the entire market. It's not 10 ideas, not 10 stocks everyone is talking about, it's what their research points to as the 10 best stocks to buy right now, and it's free. Read more here and see which stocks made the list -->>

Contact editorial@247wallst.com for any questions or corrections.